End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.15 CNY | +1.16% | -3.02% | +4.29% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- With a P/E ratio at 12.32 for the current year and 10.28 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.29% | 1.72B | - | ||
+30.66% | 682B | C+ | ||
+30.35% | 586B | B | ||
-3.60% | 364B | C+ | ||
+17.84% | 327B | B- | ||
+3.80% | 285B | C+ | ||
+15.53% | 240B | B+ | ||
+10.16% | 209B | B- | ||
-8.14% | 203B | A+ | ||
+7.89% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600211 Stock
- Ratings Tibet Rhodiola Pharmaceutical Holding Co.